German health technology company Siemens Healthineers reported on Tuesday second-quarter revenue growth slightly below consensus expectations, as it was hurt by declining revenue in China. .
The firm said it will cut costs and streamline operations by consolidating its immunoassay and clinical chemistry offerings into the Atellica Solution lineup and phase-out older platforms.